Clinical Trial

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Study acronym: FIT-001
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Protocol Amendment History 2 changes
notable Trial sites expanded: 37 -> 40 locations 2026-04-15
notable Trial sites expanded: 32 -> 37 locations 2026-04-10
Trial Details
NCT Number NCT06026410
Lead Sponsor Kura Oncology, Inc.
Collaborators: Mirati Therapeutics Inc.
Conditions Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
Enrollment 300 participants
Start Date 2023-10-18
Primary Completion 2027-01 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-08